Very early phases but I like that it’s biomarker based. And tested on actual people with schizophrenia, not healthy volunteers.
According to the company, the small-molecule type 3 serotonin receptor antagonist was able to normalise mismatch negativity (MMN) brainwaves, which act as a biomarker of cortical dysfunction.
Nice post 151515.
As we say,in the case,if you do not put in your account the existence of the psychotic factor and its effect on the self-thoughts pathways ,the treatment becomes an experimental therapeutics ,that does not target the actual casual agents who is responsible to induces all symptoms